Management of Pheochromocytoma in The Setting of Acute Stroke

Solomon Oak1,2, Mahsa Javid1,3,2, Glenda G Callender1

  • 1From the Department of Surgery, Section of Endocrine Surgery, Yale University School of Medicine, New Haven, Connecticut.

PubMed

Stroke is a rare presenting symptom of pheochromocytoma; therefore, a balance between adequate pre-operative medical blockade and expedition of surgery to minimize the risk of further peri-operative stroke is needed. However, currently there are no established guidelines regarding timing of surgery or length of pre-operative blockade in these patients. We report a case of pheochromocytoma in a 53-year-old woman presenting with a hemorrhagic transformation of an ischemic stroke. We describe the clinical course, diagnosis, and management of our case and then discuss similar cases in the literature as well as optimal pre-operative management. We review all clinical data and describe the patient presentation and treatment. A comprehensive literature review of the topic is discussed. Pheochromocytoma in our patient presented as a combination of stroke, severe hypertension, and tachycardia. A computed tomography scan, evaluation of catecholamine levels, and 123iodine-labeled metaiodobenzylguanidine scan confirmed pheochromocytoma. Hemodynamic stability was achieved after 9 weeks of treatment with selective alpha-blockade and other antihypertensive medications, after which laparoscopic transabdominal adrenalectomy was performed. Despite a normal blood pressure at pre-induction, the patient experienced 6 episodes of severe hypertension intra-operatively. There were no operative complications and hypertension resolved postoperatively. A review of the literature identified 5 similar cases; however, the optimal management of these patients remains unclear. Our case highlights the importance of including pheochromocytoma in the differential diagnosis of patients with stroke. Optimal results may be achieved by ensuring at least 6 weeks of recovery following stroke, and inducing orthostatic hypotension for at least 2 weeks prior to the surgery. Abbreviation: CT computed tomography.

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
693
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
107
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
501
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
514
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
161